tumor specific prodrug of TGFβR inhibitor

QW dosing, improved tumor-to-heart ratio

BMS-986260 prodrug w/ self-immolative link.

Journal of Medicinal Chemistry

Bristol Myers Squibb, Princeton, NJ

Chemical structure of "compound 10" BMS TGFβR inhibitor prodrug

The BMS TGFβR inhibitor prodrug, “compound 10,” demonstrates antitumor efficacy comparable to the parent compound (BMS-986260) in a syngeneic model with once-weekly dosing, while reducing the systemic exposure of…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: